{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:07:20Z","timestamp":1753880840860,"version":"3.41.2"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Botulinum neurotoxins (BoNTs), the most poisonous substances known in nature, pose significant concern to health authorities. The only approved therapeutic for botulism is antitoxin. While administered to patients only after symptom onset, antitoxin efficacy is evaluated in animals mostly in relation to time postintoxication regardless of symptoms. This is most likely due to the difficulty in measuring early symptoms of botulism in animals. In this study, a rabbit spirometry model was developed to quantify early respiratory symptoms of type E botulism that were further used as a trigger for treatment. Impaired respiration, in the form of a reduced minute volume, was detected as early as 18.1 \u00b1 2.9 h after intramuscular exposure to 2 rabbit 50% lethal doses (LD\n            <jats:sub>50<\/jats:sub>\n            ) of BoNT serotype E (BoNT\/E), preceding any visible symptoms. All rabbits treated with antitoxin immediately following symptom onset survived. Postsymptom antitoxin efficacy was further evaluated in relation to toxin and antitoxin dosages as well as delayed antitoxin administration. Our system enabled us to demonstrate, for the first time, full antitoxin protection of animals treated with antitoxin after the onset of objective and quantitative type E botulism symptoms. This model may be utilized to evaluate the efficacy of antitoxins for additional serotypes of BoNT as well as that of next-generation anti-BoNT drugs that enter affected cells and act when antitoxin is no longer effective.\n          <\/jats:p>","DOI":"10.1128\/aac.02379-17","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T14:34:53Z","timestamp":1517495693000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy"],"prefix":"10.1128","volume":"62","author":[{"given":"Eran","family":"Diamant","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Pass","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osnat","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Ben David","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amram","family":"Torgeman","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Barnea","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Tal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Rosner","sequence":"additional","affiliation":[{"name":"Veterinary Center for Pre-clinical Research, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zichel","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.012658"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/DMP.0b013e318158c5fd"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.44.3.419-448.1980"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/508176"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.2.451"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6429a6"},{"key":"e_1_3_2_9_2","volume-title":"Bioterrorism agents\/diseases","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Bioterrorism agents\/diseases. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp."},{"key":"e_1_3_2_10_2","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","author":"Centers for Disease Control and Prevention.","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"Infant botulism treatment and prevention program","author":"Division of Communicable Disease Control, California Department of Public Health","key":"e_1_3_2_11_2","unstructured":"Division of Communicable Disease Control, California Department of Public Health. Infant botulism treatment and prevention program. California Department of Public Health, Sacramento, CA. http:\/\/www.infantbotulism.org\/."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2012.08.005"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.09.030"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9060180"},{"key":"e_1_3_2_15_2","volume-title":"Prescribing information for BAT","author":"US Food and Drug Administration","year":"2017","unstructured":"US Food and Drug Administration. 2017. Prescribing information for BAT. US Food and Drug Administration, Washington, DC. https:\/\/www.fda.gov\/downloads\/...\/UCM345147.pdf."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9100309"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/444507"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90988-4"},{"key":"e_1_3_2_19_2","first-page":"357","volume-title":"UJNR Joint Panels on Toxic Micro-organisms and US Department of the Interior","author":"Iida H","year":"1970","unstructured":"Iida H. 1970. Epidemiological and clinical observations of botulism outbreaks in Japan, p 357\u2013359. In Herzberg M (ed), Proceedings of the First U.S.-Japan Conference on Toxic Microorganisms. UJNR Joint Panels on Toxic Micro-organisms and US Department of the Interior, Washington, DC."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2015.11.010"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-9542-4_52"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02121011"},{"key":"e_1_3_2_23_2","first-page":"344","article-title":"Experimental studies on the serum therapy of type E botulism: the relationship between the amount of toxin in the blood and the effect of antitoxic serum","volume":"23","author":"Iida H","year":"1970","unstructured":"Iida H, Ono T, Karashimada T. 1970. Experimental studies on the serum therapy of type E botulism: the relationship between the amount of toxin in the blood and the effect of antitoxic serum. Jpn J Med Sci Biol 23:344\u2013347.","journal-title":"Jpn J Med Sci Biol"},{"key":"e_1_3_2_24_2","first-page":"282","article-title":"Studies on the serum therapy of type E botulism: absorption of toxin from the gastrointestinal tract","volume":"23","author":"Iida H","year":"1970","unstructured":"Iida H, Ono T, Karashimada T, Ando Y. 1970. Studies on the serum therapy of type E botulism: absorption of toxin from the gastrointestinal tract. Jpn J Med Sci Biol 23:282\u2013285.","journal-title":"Jpn J Med Sci Biol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/120.5.534"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken1952.23.177"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(79)90103-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7124863"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00405-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins4121565"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01084-09"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.07.005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2010.06.010"},{"key":"e_1_3_2_34_2","volume-title":"Proc 49th Interagency Botulism Res Coord Committee (IBRCC)","author":"Mimran A","year":"2012","unstructured":"Mimran A, Chay Y, Barnea A, Halperin G, Reuveny S, Zichel R. 2012. Evaluating the efficacy of post-clinical symptom anti-toxin therapy in a mouse model of botulism A and B. Proc 49th Interagency Botulism Res Coord Committee (IBRCC), Baltimore, MD."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2010.526943"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M710442200"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.6.1281"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(98)00775-7"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008302107"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1039\/9781849737913-00167"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/42.3.209"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196892209"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186892"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-9454-6_13"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.6.4.587-590.1972"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.72.4.455-460.1956"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken1952.10.383"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1992.tb16679.x"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087089"},{"key":"e_1_3_2_50_2","volume-title":"European Pharmacopoeia","author":"European Directorate for the Quality of Medicines and Healthcare","year":"2014","unstructured":"European Directorate for the Quality of Medicines and Healthcare. 2014. European Pharmacopoeia, 8th ed, vol 1, p 1029. EDQM Council of Europe, Strasbourg, France.","edition":"8"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1263(200007\/08)20:4<273::AID-JAT657>3.0.CO;2-X"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02379-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02379-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:06:58Z","timestamp":1645477618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02379-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.02379-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02379-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02379-17"}}